RIPK1 and osteosarcoma: Thus, our data suggest that although IAP antagonist/TNFα treatment of osteosarcoma cells normally leads to ripoptosome-mediated apoptosis, suppression of caspase activity in osteosarcoma cells treated with these agents provokes cell death that is primarily RIPK1-dependent but does not necessarily require RIPK3.